Graft arteriopathy, a leading cause of cardiac allograft failure, is associated with increased intimal smooth muscle cells, inflammatory cells, and accumulation of extracellular matrix. We hypothesized that cellular fibronectin plays a pivotal role in the progression of the allograft arteriopathy by directing the transendothelial trafficking of inflammatory cells through interaction of the connecting segment-i (CS1) motif with the very late antigen-4 (VLA-4) integrin, and tested this in vivo using a blocking peptide. Cholesterolfed rabbits underwent heterotopic cardiac transplantation without immunosuppression. The treatment group (n = 7) received a synthetic CS1 peptide (1 mg/kg per d, subcutaneously), and the controls (n = 7) received an inactive peptide (1 mg/kg per d, subcutaneously). At 7-8 d after transplantation, hearts were harvested and sectioned for morphometric analysis and immunohistochemical studies. We observed a > 50% decrease in the incidence (P < 0.001) and severity (P < 0.001) of donor coronary artery intimal thickening in the CS1-treated compared with the control group. These findings correlated with reduced infiltration of T cells (P < 0.05), a trend toward decreased expression of adhesion molecules (P < 0.06), and less accumulation of fibronectin (P < 0.03). Our data suggest that the VLA-4-fibronectin interaction is critical to the progression of the allograft arteriopathy by perpetuating the immune-inflammatory response in the vessel wall. (J. Clin. Invest 1995Invest . 95:2601Invest -2610
Introduction
The results of cardiac transplantation have been improved considerably by the advent of better immunosuppression therapy, but long-term survival is often limited by rapidly developing coronary arteriopathy (1) . The pathophysiology of this complication has been studied extensively and an immune-inflammatory response is believed to be a cause of progressive coronary artery neointimal thickening. The process involves the recruitment of inflammatory cells and release of soluble factors, i.e., cytokines and growth factors, leading to smooth muscle cell migration and proliferation and deposition of newly formed extracellular matrix (2) (3) (4) . These soluble factors also modulate the functional status of circulating immune-reactive cells and the vascular endothelium, allowing interaction through the expression and activation of receptors and counterreceptors, i.e., intercellular adhesion molecule-I (ICAM-1 and vascular cell adhesion molecule-I (VCAM-1) (5, 6) .
Various extracellular matrix components appear to have a determining role in lymphocyte trafficking (7) through their interaction with cell surface antigens, namely integrin receptors (8) , and the latter, in turn, exert synergistic effects on T cell activation (9, 10) and cytokine release (10) . The potential of fibronectin, an extracellular matrix component, as a ligand for lymphocytes has been extensively investigated (7, 8, (11) (12) (13) . The presence of receptors on lymphocytes that bind fibronectin has suggested that this molecule plays a role in lymphocyte adhesion (11) . The a4,i1 (also called very late antigen-4
[VLA -4] ) and a5f/h (also called VLA-5) integrins, present on a variety of cells including lymphocytes, bind to specific sites on the fibronectin molecule, i.e., the connecting segment-i (CS1) motif present in an alternatively spliced (V) region (8, 14) and the arginine-glycine-aspartate (RGD) sequence present in the cell adhesion domain (15) (16) (17) , respectively. It has been shown that interactions between fibronectin and inflammatory cells, including eosinophils and monocytes as well as lymphocytes, enhance migration (16, (18) (19) (20) . Fibronectin potentiates lymphocyte proliferation (9, 15) and also prolongs eosinophil survival in culture by triggering production of cytokines (21) .
Takeuchi et al. (22) reported that increased expression of VLA-4 molecules in peripheral blood lymphocytes of systemic lupus erythematosus patients with vasculitis was associated with enhanced adhesion to the CS1 motif of fibronectin in vitro. Similar findings were published by Laffon and colleagues (23) when they analyzed T cells from the inflamed synovium of patients with rheumatoid arthritis. Since VLA-4 integrin receptors are upregulated on inflammatory cells, a useful therapeutic strategy may be to block interactions with its counterreceptors on endothelial cell surfaces or with fibronectin, by specific antibodies or synthetic peptides. In this regard, Elices et al. (24) have recently reported CS I-containing fibronectin isoforms on the synovial endothelium of rheumatoid arthritis patients and, also, that adhesion of T lymphoblastoid cells to this endothelium could be abrogated either by an anti-a4 integrin antibody or by the CS1 peptide. In addition, CS1 peptide was shown to decrease lymphocyte migration through high endothelial venule cells, reinforcing a role for fibronectin in the recruitment of these inflammatory cells (25) .
We have demonstrated previously in vivo that an immuneinflammatory response in donor coronary arteries was associated with increased expression of both fibronectin and IL-1p, using a piglet heterotopic cardiac transplant model of induced allograft arteriopathy (26) . Further in vitro studies showed that donor coronary artery endothelial and smooth muscle cells produced increased amounts of fibronectin which was regulated by increased endogenous IL-1p (3, 4) and TNF-a (27). The functional significance of this feature was pursued using a heterotopic cardiac transplant model in cholesterol-fed rabbits in which anticytokine therapy, namely TNF-a soluble receptor (TNF-asr), effectively decreased the incidence and severity of graft arteriopathy (28) . Mechanistically, this was associated with decreased expression of fibronectin and a reduced immuneinflammatory response, including downregulation of ICAM-1 and VCAM-1 expression (29) , in the treated animals compared with controls (28) . Taken together these observations suggest that the increased subendothelial fibronectin, in addition to its potential role in directing smooth muscle cell migration (30) , may be responsible for trafficking of immune-inflammatory cells through the vessel wall.
This study was, therefore, carried out to address in vivo, using an experimental rabbit cardiac transplant model, the role of fibronectin in mediating transendothelial lymphocyte trafficking and in influencing the development and severity of the accelerated graft arteriopathy. 1 wk after cardiac transplantation, we observed a > 50% reduction in the number and severity of allograft coronary artery lesions in a group of animals treated with CS1 peptide compared with a control group, where a scrambled (inactive) form of CS1 peptide was used. The decreased neointimal formation was associated with reduction in T cell infiltration, expression of cell adhesion molecules, and accumulation of fibronectin. Severe (28) . 14 animals in total were studied in the control (n = 7) and CSl-treated (n = 7) groups.
Preparation of the hearts. The animals were killed using a lethal dose of euthanol (480 mg intravenously) (MTC Pharmaceutical, Cambridge, Ontario, Canada), host and donor hearts were removed, and the coronary arteries were perfused with saline through the aorta and followed by light fixation by perfusion with 2% paraformaldehyde (Sigma Immunochemicals, St. Louis, MO). Because of previous descriptions indicating that cardiac allograft arteriopathy in the rabbit was equally distributed throughout the coronary circulation (34) Quantitative assessment of host and donor coronary arteries by light microscopy Three different paraffin-embedded tissue sections from host and donor hearts from both control and CS 1-treated rabbits were stained by the Movat pentachrome method for light microscopy. Morphometric analysis was performed using a Zeiss microscope attached to a computergenerated video analysis system (NuVision Software, Perceptics Inc., Knoxville, TN), as described previously (28) . The number of vessels with intimal lesions was counted in all three heart sections from each experimental animal and was expressed as a percentage of total vessel number. In the host hearts, 999 vessels in the control group and 1,054 vessels in the CS1-treated group were analyzed. In the donor hearts, 827 vessels in the control group and 617 vessels in the CS1-treated tim), medium (diameter > 100 < 500 ,m), and large (diameter > 500 Jsm). The degree of intimal thickening was then quantitatively assessed in each vessel size category as previously described (36 vat pentachrome-stained histologic sections, we observed a similar small proportion of coronary arteries with intimal thickening in host hearts from both control (scrambled peptide) and CS1-treated groups (10±1 and 12±2% SEM, respectively) ( Fig. 1) . In donor hearts from the control group, however, 87±4% SEM of the vessels had intimal thickening, whereas in the CS1-treated group only 35±2% SEM were affected (P < 0.001 for small size vessels and P < 0.05 for medium size vessels) (Fig. 1) . The proportion of coronary arteries with intimal thickening, in CS1 and control groups, was similarly distributed in the small (5 100 tm diameter) and medium (> 100 5 500 Mm diameter) size ranges; however, the large coronary arteries (> 500 Am diameter) were mostly spared.
The severity of the lesions, judged by the area of intimal thickening as a proportion of total vessel area, was similar in host coronary arteries from both control and CS 1-treated groups (12±1 and 12±1% SEM, respectively) (Fig. 2) . Intimal thickening in donor coronary arteries from control animals was three times more severe than that in host vessels, i.e., 36±2% SEM of total vessel area. In the CS 1-treated group, intimal thickening was only 16±2% SEM (P < 0.001) (Fig. 2) . A similar reduction in the severity of intimal lesions in the CS1-treated compared with the control group was observed in both small ( < 100 Am diameter) and medium (> 100 < 500 sm diameter) size vessels. Representative examples of coronary arteries in the host, donor control, and donor CS1-treated animals are shown in Fig. 3 , A-C, respectively. In addition, Fig. 4 A is representative of extensive intimal thickening affecting small vessels in the control group which contrasts with Fig. 4 There was significant reduction in the severity of intimal thickening in both small (diameter s 100 mm) and medium (diameter > 100 r 500
,im) size vessels of CS1-treated animals, compared with the control (scrambled CSl) group (P < 0.001), and that approached host levels.
No differences in both groups were seen in host vessels, where the severity of intimal lesions was similarly low.
hearts (Fig. 3 D) , myocardial rejection was of equal severity in donor control and donor CS1-treated hearts as judged by extensive lymphocytic infiltration and myocyte necrosis, hemorrhage, and fibrosis (Fig. 3, E and F, respectively) .
Immune-inflammatory markers in the coronary arteries. Immunohistochemical studies were performed to compare expres-A '.. sion of MHC class II molecules, T cells, and macrophages in host and donor coronary arteries from control and CS1-treated groups. Host coronary arteries were negative for these inflammatory markers. Fig. 5 , A and D, shows examples of negative immunostaining for MHC H and T cells, respectively. In donor hearts, however, there was enhanced expression of these markers of inflammation, albeit differing markedly in intensity in both control and CS 1-treated animals. In five out of seven control animals, increased expression for MHC II molecules ( ++ to +++) was observed in donor coronary arteries (Fig. 5 B) , whereas in the CS1-treated group immunostaining in only two out of seven animals was abundant (++), and was minimal (+, ±) or negative (-) in the remainder (Fig. 5 C) (Table I) . While the difference in MHC expression was not reflected in statistical significance, we were able to show that CSI treatment significantly decreased the presence of T cells in the coronary arteries (Fig. 5 F) . While five out of seven animals in the control group showed positive immunostaining of + ± to + + ±, only one of seven CS1-treated animals showed > + (++) expression (Fig. 5 E) (P < 0.05) ( Table I ). Of note is the observation that the infrequent T cells observed in the CS1-treated group appeared to be mostly on the luminal surface (Fig. 5 F) and also in the adventitia (Fig. 5 H) with few cells seen infiltrating the vessel wall. On the other hand, the control group showed an increased proportion of T cells infiltrating the vessel wall ( Fig. 5 E, arrow) , as well as present on the luminal surface (Fig. 5 E) and adventitia (Fig. 5 G) . Macrophages were seldom observed in the host coronary arteries, and their presence in donor coronary arteries of both groups was also low, with no appreciable differences observed (Table I) Thes difference iICMmunsainigoi theprcontrola an S1tetdgoptrendd towardstitca significance (P < 0.06). nbt oto (able I). Likewise, VCgaMive expressionwaprssioncrae in tdheso donorlecoronrylartedriehlw ees of theotrlgopre (Fig. 6fE) , wIth four out of seven aniabls s)hrahowinger, intensiteoimmunoCsio 1-rete group, wherVCAM-1 aexpressionews, sminiai borh absent (Fig. 6o F) with intimal thickening and with reduced severity of the lesions in the control group (Table I) .
Discussion
In this study, we describe the positive effect of a synthetic tetrapeptide, a short form of the CS I peptide, in interfering with the development of experimental graft arteriopathy in vivo by specifically blocking the interaction between the a4f61 integrin receptor with the cell-associated matrix protein fibronectin. This peptide may also interfere with the transendothelial lymphocyte migration that is dependent on the interaction with the VCAM-1 receptor on endothelial cell surfaces, albeit at much higher doses than those effective in blocking binding to fibronectin (37, 38) . We were able to show a decrease in both the incidence and severity of allograft coronary artery lesions in the CS1-treated compared with the control group, despite the fact that severe myocardial rejection was similar in both groups. Moreover, we observed a significant reduction in the infiltration of T cells in coronary arteries associated with a marked decrease in subendothelial fibronectin accumulation. Trends toward reduced expression of cell adhesion molecules (ICAM-1 and VCAM-1) were also observed. These results indicate that blocking the initial interaction between fibronectin and T cells alleviates the subsequent cytokine-mediated upregulation of fibronectin which we have shown contributes to the intimal thickening (26, 28) . In addition, CS1 may directly block vascular smooth muscle fibronectin interaction and interfere with their migration into the subendothelium (30) . This novel strategy which targets integrin receptors that are upregulated on the surface of immune-reactive cells, and expressed on vascular smooth muscle cells (39, 40) , by blocking their interaction with cellular fibronectin, suggests an adjuvant therapeutic approach which may be useful in preventing or reducing the severity of graft arteriopathy.
The rabbit cardiac allograft model has been useful in studying a variety of pathophysiologic mechanisms either related to In the control group, T cells were abundant both on the endothelial surface and infiltrating the vessel wall (E, arrow). The presence of T cells was significantly reduced in the CS1 group, and when seen on the coronary arteries they were mostly adherent to the endothelial surface (F). T cells could also be seen in the adventitia of coronary arteries in both CS 1-treated (H) and control groups (G). Original magnifications of 40 (A-F; insets at an original magnification of 100) and 100 (G and H).
the process of myocardial rejection or to the development of graft arteriopathy (31, 41) . Despite the accelerated time course of the arteriopathy in this model (28, 31) , the rabbit allograft arterial lesions resemble those observed in human allografts (41) and, therefore, the model offers the advantage of investigating, within a relatively short period of time, the pathophysiologic factors likely to be involved. It is the lack of immunosuppression that results in a shorter experimental time frame of 7-8 d as formerly described in this model (28, 31) , since our previous studies have shown that neointimal thickening is not prominent in animals that are immunosuppressed (28) . A hypercholesterolemic diet was also introduced in the rabbit cardiac allograft model to further hasten the development of the arteriopathy (31), since rabbits have low systemic cholesterol levels (42) , and also to more closely simulate the clinical setting, since hyperlipidemia is one of the risk factors accelerating the appearance of intimal lesion in human cardiac allografts (1, 43) . The effect of a 0.5% cholesterol diet in the rabbit is reflected in increased circulating lipid levels (31), as well as the induction of early intimal lesions in host vessels, as judged by an average of 10-12% of vessels affected and a similar degree of vessel area with intimal thickening (12%) . Furthermore, we have observed fatty infiltration of the myocardium in rabbit allografts subjected to this diet (28) .
The upregulation of integrin receptors, i.e., VLA-2, VLA-4, and VLA-6, has been shown in lung and heart biopsies of transplant patients undergoing episodes of rejection (44, 45) . In addition, increased expression of matrix proteins bearing in their structure ligands for some of these integrins, i.e., fibronectin and laminin, was reported in rejected cardiac (46) and renal (47) allografts. These studies suggest that matrix could be involved in the recruitment of immune-reactive cells. Since the process of inflammatory cell emigration into tissues involves expression of adhesion molecules, e.g., ICAM-1, VCAM-1, and P-and E-selectins on the endothelium (48, 49) , there is increasing evidence that matrix proteins might further contribute by encouraging transendothelial migration and positioning.
In our study, we investigated the potential role of the interaction between the VLA-4 integrin and the CS1 motif in the fibronectin molecule in modulating inflammatory cell traffick- of intimal lesions, i.e., 1 wk without immunosuppressive therapy in this report versus 5-6 wk in the presence of immunosuppressive therapy in the aforementioned studies. The expression of MHC class II molecules, which we described previously as part of the immune-inflammatory reaction in the allograft vessels after heterotopic heart transplantation (26, 28) , was observed in both CS 1-treated and control groups. This suggests that CS1 peptide may not have completely suppressed the process of antigen presentation occurring in the setting of an allograft response (51) . That the transendothelial infiltration of T cells was, however, effectively reduced in vivo in the CS1-group provides evidence, for the first time, of a functional role for cellular fibronectin in the trafficking of inflammatory cells in graft arteriopathy. This is supported by our recent in vitro studies using an endothelial-smooth muscle cell coculture system, in which we have shown that fibronectin regulates lymphocyte transendothelial migration (52 On the other hand, given the efficacy with which CS1 blocked the neointimal thickening in coronary arteries, it is tempting to speculate that it interfered not only with the trafficking of inflammatory cells into the subendothelium but also with the migration of smooth muscle cells from the media into the intima. That is, the a4131 integrin which binds the CS1 peptide is also expressed on smooth muscle cells (17, 39, 40) and we (30) and others (53) TNF-a (3, 4, 27) , and it is likely that release of these cytokines from inflammatory cells leads to their induction in vascular cells (2) . Macrophages were observed less frequently in the donor coronary arteries of both experimental groups, and this is in keeping with our previous in vivo studies in rabbits and piglets in which macrophages were not a prominent early feature of the accelerated graft arteriopathy. Kuwahara et al. (42) have reported the presence of macrophages in vascular lesions from rejected rabbit cardiac allografts at 2 and 3 wk after transplantation, with only lymphocytes evident after 1 wk. Lipid-laden macrophages are certainly evident in coronary arteries in patients that develop graft arteriopathy years after cardiac transplantation (54) . Macrophages were also seen at venular sites among the clusters of inflammatory cells, including T cells, infiltrating the rejected myocardium in both CS1-treated and control groups, findings similar to those demonstrated in other studies (55) . The expression of adhesion molecules was also intense at these venular sites. This would indicate that different qualitative or quantitative factors are responsible for myocardial rejection and graft arteriopathy. Thus, this supports our previous experience with the TNF-asr which preferentially also blocked graft arteriopathy but not myocardial rejection, as well as clinical experience showing that graft arteriopathy occurs despite immunosuppressive therapy and absence of acute episodes of rejection (56) .
In summary, we have used specific reagents to show that the reduction of an accelerated form of graft arteriopathy, induced in cholesterol-fed rabbits after cardiac transplantation, can be achieved by blockade of the interaction between VLA-4 integrin and cell-associated fibronectin. We propose that this halts the subsequent cytokine-dependent cascade of events resulting from activated T cell subendothelial trafficking and positioning. The latter involves upregulation of adhesion molecules and further induction of fibronectin expression. Treatment with CSl specifically blocked vascular changes, since myocardial rejection was as severe in this group of animals as in the control group. Therefore, it is possible that targeting the interaction between fibronectin and VLA-4 on immune-inflammatory cells may offer adjuvant therapies effective in preventing graft arteriopathy.
